HIF-1α is reported to prompt OCT4 and SOX2 to bind to the PROM1 promoter and increase the population of stem cells.16 HIF-1α directly targets the Hippo pathway effector, TAZ and regulates cancer stemness.17 The Notch, and Wnt/β-catenin pathways are also mediated by HIF-1α in CSCs.18 In addition, HIF-1α drives the transcription of the enzymes GLUT1, HK2, and LDHA, which are the key enzymes of tumor glycolysis.19 HIF-1α contributes to drug resistance, including chemoresistance and TKIs. The gene discussed is HIF1A; the disease is neoplasm.